跳到主要内容

新闻与日历

新闻: 截至 2026-10-07
这些标记是什么意思

重要性是模型对已发布报道给出的 1–5 分,不是对市场的预测。

已排定事件行上的影响是公司显著度层级(高/中由图谱中心度与规模判定;低仅用于人工整理的次要事件),不是对波动幅度的预测。

标记为已确认的财报日期,是 Yahoo Finance 认定由公司确认的;预估表示尚未公布。未加标记的行没有可查的出处记录。

经济数据发布属于宏观、不归属任何产业,因此在任何视图下都会保留。没有数值的发布表示尚未公布,页面会直说,而不是显示为零。

涵盖被追踪公司的即将到来的事件;已过去的事件会归档,并在可得时补上结果——这些结果都经人工整理并附引用,绝不杜撰。没有结果的历史行会显示“结果待定”。

解禁或指数调整的行会多出一行算术——将变得可卖出的股数,或指数基金必须买入的股数,以占流通股的比例表示——依据招股说明书或指数编制方法读出,两个数字都在该行注明出处。它陈述的是机制,不是价格走势。由 IPO + 180 天推算出的解禁日期会一直标为预估,直到公司自己说明为止。

未来

已排定 · 今天与明天 · 日历更新于 2026-10-12

10月12日周一 · 今天

10月13日周二

过往

已发布 · 最新在前

8月28日周五

产品

07:00
GlobeNewswire

Roche's Vabysmo shows sustained two-year results in difficult-to-treat nAMD

Roche reported that Vabysmo demonstrated sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration. This is follow-up data on an already-approved product, so it is graded as incremental.

大盘 打开原文 ↗

8月27日周四

财报

15:43
Yahoo Finance

Canadian Solar Q2 Loss Wider Than Estimates, Revenues Fall Y/Y

Canadian Solar reported a Q2 2026 loss of $1.40 per share versus a consensus estimate of a $1.01 loss and a year-ago loss of $0.08. Revenue of $1.21 billion topped the $1.17 billion consensus but fell 28.7% from $1.69 billion a year earlier, and solar modules recognized as revenue totaled 3.1 gigawatts, down 25% year over year. The company guided Q3 revenue to $1.30-$1.50 billion with gross margin of 13.5%-15.5%, below the $1.65 billion Q3 consensus cited in the article.

大盘 打开原文 ↗

产品

15:00
Yahoo Finance

RTX's Raytheon completes $50 million expansion of Mississippi manufacturing facility

RTX's Raytheon business completed a $50 million, 17,000 square-foot expansion of its Forest, Mississippi plant, bringing the site to 445,000 square feet of manufacturing space. The facility builds electronic warfare and radar systems including Next Generation Jammer Mid-Band pods for the U.S. Navy and the Australian government, and the expansion is expected to add 100 high-skill positions by 2028.

大盘 打开原文 ↗

合作

12:50
GlobeNewswire

argenx completes acquisition of Forte Biosciences

argenx announced it has completed its acquisition of Forte Biosciences, Inc. Forte is not in this universe, so it is not listed as a counterparty. Consideration is not stated in the headline and is not reproduced here.

大盘 打开原文 ↗

产品

11:30
Clinical Trials Arena

Amgen-AstraZeneca's Tezspire nets another Phase III inflammatory disease win

Tezspire, co-developed by AstraZeneca and Amgen, hit its endpoints in a Phase 3 trial in eosinophilic esophagitis, opening a potential new indication.

大盘 打开原文 ↗

原始消息流

所有到达的消息 · 7 天